In this analysis of a large cohort of women who acquired HIV infection while receiving oral or vaginal tenofovir-based PrEP, we observed no clinically significant impact of study treatment on subsequent HIV disease parameters, including viral set point and change in HIV RNA or CD4+ T cell count in the first year of infection. The gene discussed is CD4; the disease is infection.